Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Robert W Belknap

TitleAffiliate - DHHA
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/315-7424

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Vonnahme LA, Raykin J, Jones M, Oakley J, Puro J, Langer A, Aiona K, Belknap R, Ayers T, Todd J, Winglee K. Using Electronic Health Record Data to Measure the Latent Tuberculosis Infection Care Cascade in Safety-Net Primary Care Clinics. AJPM Focus. 2023 Dec; 2(4):100148. PMID: 37941821.
      View in: PubMed
    2. Zavala S, Winglee K, Ho CS, Pettit AC, Ahmed A, Katz DJ, Belknap RW, Stout JE. Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in People Born Outside the United States. Ann Am Thorac Soc. 2023 09; 20(9):1258-1266. PMID: 37159954.
      View in: PubMed
    3. Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, Millet JP, Cayl? JA, Scott NA, Borisov A, Gandhi NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023 06 16; 76(12):2090-2097. PMID: 36815322.
      View in: PubMed
    4. Scott NA, Sadowski C, Vernon A, Arevalo B, Beer K, Borisov A, Cayla JA, Chen M, Feng PJ, Moro RN, Holland DP, Martinson N, Millet JP, Miro JM, Belknap R. Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine. Contemp Clin Trials. 2023 06; 129:107173. PMID: 37004811.
      View in: PubMed
    5. Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 09; 11(9):782-790. PMID: 36966788.
      View in: PubMed
    6. Winglee K, Hill AN, Belknap R, Stout JE, Ayers TL. Variability of interferon-? release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States. Clin Microbiol Infect. 2022 Jul; 28(7):1023.e1-1023.e7. PMID: 35183749.
      View in: PubMed
    7. Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 12; 18(12):e1003875. PMID: 34914696.
      View in: PubMed
    8. Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis. Clin Infect Dis. 2021 11 02; 73(9):e3459-e3467. PMID: 32915203.
      View in: PubMed
    9. Pettit AC, Stout JE, Belknap R, Benson CA, S?raphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS. Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021 10 05; 73(7):e2278-e2284. PMID: 32761083.
      View in: PubMed
    10. Radtke KK, Ernest JP, Zhang N, Ammerman NC, Nuermberger E, Belknap R, Boyd R, Sterling TR, Savic RM. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study. Antimicrob Agents Chemother. 2021 11 17; 65(12):e0170521. PMID: 34606336.
      View in: PubMed
    11. Feng PJ, Wu Y, Ho CS, Chinna L, Whelen AC, Largen A, Brostrom R, Reves R, Belknap R, Cattamanchi A, Banaei N. Impact of T-Cell Xtend on T-SPOT.TB Assay in High-Risk Individuals after Delayed Blood Sample Processing. J Clin Microbiol. 2021 04 20; 59(5). PMID: 33658266.
      View in: PubMed
    12. Gaensbauer J, Young J, Harasaki C, Aiona K, Belknap R, Haas MK. Interferon-Gamma Release Assay Testing in Children Younger Than 2 Years in a US-Based Health System. Pediatr Infect Dis J. 2020 09; 39(9):803-807. PMID: 32804462.
      View in: PubMed
    13. Flynn AG, Aiona K, Haas MK, Reves R, Belknap R. Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2020 08 22; 71(5):1320-1323. PMID: 31773132.
      View in: PubMed
    14. Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020 08 12; 15(1):65. PMID: 32787925.
      View in: PubMed
    15. Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. Am J Respir Crit Care Med. 2020 07 15; 202(2):305-306. PMID: 32282235.
      View in: PubMed
    16. Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. Am J Respir Crit Care Med. 2020 03 01; 201(5):598-605. PMID: 31711306.
      View in: PubMed
    17. Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020 02 14; 69(1):1-11. PMID: 32053584.
      View in: PubMed
    18. Haas MK, Belknap RW. Diagnostic Tests for Latent Tuberculosis Infection. Clin Chest Med. 2019 12; 40(4):829-837. PMID: 31731987.
      View in: PubMed
    19. Venkatappa TK, Punnoose R, Katz DJ, Higgins MP, Banaei N, Graviss EA, Belknap RW, Ho CS. Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection. J Clin Microbiol. 2019 11; 57(11). PMID: 31462550.
      View in: PubMed
    20. Sosa LE, Njie GJ, Lobato MN, Bamrah Morris S, Buchta W, Casey ML, Goswami ND, Gruden M, Hurst BJ, Khan AR, Kuhar DT, Lewinsohn DM, Mathew TA, Mazurek GH, Reves R, Paulos L, Thanassi W, Will L, Belknap R. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019 May 17; 68(19):439-443. PMID: 31099768.
      View in: PubMed
    21. Belknap RW. Current Medical Management of Pulmonary Tuberculosis. Thorac Surg Clin. 2019 Feb; 29(1):27-35. PMID: 30454919.
      View in: PubMed
    22. Haas MK, Belknap RW. Updates in the Treatment of Active and Latent Tuberculosis. Semin Respir Crit Care Med. 2018 Jun; 39(3):297-309. PMID: 30071545.
      View in: PubMed
    23. Chee CBE, Reves R, Zhang Y, Belknap R. Latent tuberculosis infection: Opportunities and challenges. Respirology. 2018 10; 23(10):893-900. PMID: 29901251.
      View in: PubMed
    24. Beavers SF, Pascopella L, Davidow AL, Mangan JM, Hirsch-Moverman YR, Golub JE, Blumberg HM, Webb RM, Royce RA, Buskin SE, Leonard MK, Weinfurter PC, Belknap RW, Hughes SE, Warkentin JV, Welbel SF, Miller TL, Kundipati SR, Lauzardo M, Barry PM, Katz DJ, Garrett DO, Graviss EA, Flood JM. Tuberculosis Mortality in the United States: Epidemiology and Prevention Opportunities. Ann Am Thorac Soc. 2018 06; 15(6):683-692. PMID: 29490150.
      View in: PubMed
    25. Gaensbauer J, Gonzales B, Belknap R, Wilson ML, O'Connor ME. Interferon-Gamma Release Assay-Based Screening for Pediatric Latent Tuberculosis Infection in an Urban Primary Care Network. J Pediatr. 2018 09; 200:202-209. PMID: 29866596.
      View in: PubMed
    26. Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, Leung CC, Schluger NW, Belknap RW, Chaisson RE, Narita M, Machado ES, Lopez M, Sanchez J, Villarino ME, Sterling TR. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. Ann Am Thorac Soc. 2018 05; 15(5):570-580. PMID: 29393655.
      View in: PubMed
    27. Gaensbauer J, Aiona K, Haas M, Reves R, Young J, Belknap R. Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic. Pediatr Infect Dis J. 2018 03; 37(3):224-228. PMID: 28777204.
      View in: PubMed
    28. Belknap R, Reves R. In reply: We and our patients must demand better TB diagnostics. Int J Tuberc Lung Dis. 2017 12 01; 21(12):1316. PMID: 29297457.
      View in: PubMed
    29. Belknap R, Holland D, Feng PJ, Millet JP, Cayl? JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Mir? JM, Villarino ME, Weiner M, Borisov AS. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017 11 21; 167(10):689-697. PMID: 29114781.
      View in: PubMed
    30. Belknap R, Reves R. Is it time to rethink the role of AFB smears? Int J Tuberc Lung Dis. 2017 07 01; 21(7):720. PMID: 28633694.
      View in: PubMed
    31. De Groote MA, Higgins M, Hraha T, Wall K, Wilson ML, Sterling DG, Janjic N, Reves R, Ochsner UA, Belknap R. Correction for De Groote et al., "Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection". J Clin Microbiol. 2017 05; 55(5):1598. PMID: 28442616.
      View in: PubMed
    32. De Groote MA, Higgins M, Hraha T, Wall K, Wilson ML, Sterling DG, Janjic N, Reves R, Ochsner UA, Belknap R. Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection. J Clin Microbiol. 2017 02; 55(2):391-402. PMID: 27852671.
      View in: PubMed
    33. Chaulk CP, Belknap R. A public heath 'selfie' for treating tuberculosis? Int J Tuberc Lung Dis. 2016 May; 20(5):571. PMID: 27084806.
      View in: PubMed
    34. Collins JM, Reves RR, Belknap RW. High Rates of Tuberculosis and Opportunities for Prevention among International Students in the United States. Ann Am Thorac Soc. 2016 Apr; 13(4):522-8. PMID: 26730745.
      View in: PubMed
    35. Flood J, Scott J, Belknap R. Latent Mycobacterium tuberculosis Infection. N Engl J Med. 2015 09 17; 373(12):1179. PMID: 26376153.
      View in: PubMed
    36. Belknap R, Daley CL. Interferon-gamma release assays. Clin Lab Med. 2014 Jun; 34(2):337-49. PMID: 24856531.
      View in: PubMed
    37. Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, Wang Y, Cronin W, Hirsch-Moverman Y, Teeter LD, Parker M, Garrett DO, Daley CL. Interferon-? release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014 Jan 01; 189(1):77-87. PMID: 24299555.
      View in: PubMed
    38. Saveli CC, Morgan SJ, Belknap RW, Ross E, Stahel PF, Chaus GW, Hak DJ, Biffl WL, Knepper B, Price CS. Prophylactic antibiotics in open fractures: a pilot randomized clinical safety study. J Orthop Trauma. 2013 Oct; 27(10):552-7. PMID: 23446823.
      View in: PubMed
    39. Belknap R, Weis S, Brookens A, Au-Yeung KY, Moon G, DiCarlo L, Reves R. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS One. 2013; 8(1):e53373. PMID: 23308203.
      View in: PubMed
    40. Beieler AM, Jenkins TC, Price CS, Saveli CC, Bruntz M, Belknap RW. Successful limb-sparing treatment strategy for diabetic foot osteomyelitis. J Am Podiatr Med Assoc. 2012 Jul-Aug; 102(4):273-7. PMID: 22826325.
      View in: PubMed
    41. Walter ND, Strong M, Belknap R, Ordway DJ, Daley CL, Chan ED. Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis. Respirology. 2012 Jul; 17(5):772-91. PMID: 22458269.
      View in: PubMed
    42. Gray J, Reves R, Johnson S, Belknap R. Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIV-infected patients at low risk for tuberculosis. Clin Infect Dis. 2012 Feb 01; 54(3):e20-3. PMID: 22057704.
      View in: PubMed
    43. Saveli CC, Belknap RW, Morgan SJ, Price CS. The role of prophylactic antibiotics in open fractures in an era of community-acquired methicillin-resistant Staphylococcus aureus. Orthopedics. 2011 Aug; 34(8):611-6; quiz 617. PMID: 21800816.
      View in: PubMed
    44. Young H, Swartwood CJ, Jenkins TC, Belknap R. A successful strategy for the use of synergistic intravenous streptomycin in a hemodialysis patient with refractory Enterococcus faecalis bacteremia. J Infect Chemother. 2011 Oct; 17(5):698-9. PMID: 21350946.
      View in: PubMed
    45. Spencer JS, Kim HJ, Wheat WH, Chatterjee D, Balagon MV, Cellona RV, Tan EV, Gelber R, Saunderson P, Duthie MS, Reece ST, Burman W, Belknap R, Mac Kenzie WR, Geluk A, Oskam L, Dockrell HM, Brennan PJ. Analysis of antibody responses to Mycobacterium leprae phenolic glycolipid I, lipoarabinomannan, and recombinant proteins to define disease subtype-specific antigenic profiles in leprosy. Clin Vaccine Immunol. 2011 Feb; 18(2):260-7. PMID: 21177913.
      View in: PubMed
    46. Beieler AM, Belknap RW, Dayton MR, Price CS, Morgan SJ. Eradication of multidrug-resistant Acinetobacter baumannii in a female patient with total hip arthroplasty, with debridement and retention: a case report. J Med Case Rep. 2009 Feb 03; 3:45. PMID: 19192275.
      View in: PubMed
    47. Belknap R, Wall K, Reves R. What can the NHANES data tell us about the tuberculin skin test and the risk for active tuberculosis? Am J Respir Crit Care Med. 2008 Oct 15; 178(8):883-4; author reply 884. PMID: 18832558.
      View in: PubMed
    48. Gardner EM, Kestler M, Beieler A, Belknap RW. Clostridium butyricum sepsis in an injection drug user with an indwelling central venous catheter. J Med Microbiol. 2008 Feb; 57(Pt 2):236-239. PMID: 18201992.
      View in: PubMed
    49. Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis. 2005 Sep; 9(9):1057-8. PMID: 16158902.
      View in: PubMed
    50. Koeppe J, Belknap R, Bessesen M. Mycobacterium avium complex peritonitis in the setting of cirrhosis: case report and review of the literature. Scand J Infect Dis. 2004; 36(8):615-7. PMID: 15370677.
      View in: PubMed
    Belknap's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (155) concept(s)
    _
    Co-Authors Expand Description
    See all (12) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)